Back to top

H.C. Wainwright Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

H.C. Wainwright analyst Matthew Caufield maintained a Buy rating on 4D Molecular Therapeutics on September 17 and set a price target of $36.00. The...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

4D Molecular Therapeutics, Inc. (FDMT)